MedTrace Logo

Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.

NCT00849550 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2012-12-24

No results posted yet for this study

Summary

The purpose of this study is to determine if RAD001 (everolimus) helps improve the standard treatment of XELOX-A (bevacizumab, oxaliplatin, capecitabine) in advanced solid tumors.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific
  • Cancer

Interventions

DRUG

capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)

bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral

Sponsors & Collaborators

  • Roche-Genentech

    collaborator INDUSTRY

  • Novartis

    collaborator INDUSTRY

  • Herbert Hurwitz

    lead OTHER

Principal Investigators

  • Herbert Hurwitz, MD · Duke University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00849550 on ClinicalTrials.gov